Aigen Investment Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Aigen Investment Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-19,569	Closed	-$172K	–	1073
2023 Q4	$172K	Buy	+19,569	New	+$160K	0.03%	685
2023 Q3	–	Sell	-53,988	Closed	-$1.37M	–	1131
2023 Q2	$1.37M	Buy	53,988 +42,150	+356%	+$1.31M	0.2%	137
2023 Q1	$381K	Sell	11,838 -24,412	-67%	-$761K	0.05%	366
2022 Q4	$669K	Buy	+36,250	New	+$829K	0.09%	220
2021 Q3	–	Sell	-7,866	Closed	-$233K	–	691
2021 Q2	$233K	Buy	+7,866	New	+$227K	0.04%	375
2020 Q4	–	Sell	-26,199	Closed	-$659K	–	1145
2020 Q3	$659K	Buy	26,199 +14,839	+131%	+$389K	0.08%	350
2020 Q2	$277K	Buy	11,360 +3,442	+43%	+$67.9K	0.04%	633
2020 Q1	$117K	Sell	7,918 -1,295	-14%	-$26.8K	0.02%	833
2019 Q4	$150K	Buy	+9,213	New	+$143K	0.02%	609

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aigen Investment Management's RVNC Position: Q1 2024 in Review

Aigen Investment Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2024, closing a stake of 19,569 shares — an estimated $172K sold.

Aigen Investment Management first reported a position in RVNC in Q4 2019 and held it in 9 quarters. The position peaked at $1.37M in Q2 2023. 188 funds tracked by Wall St. Rank hold RVNC as of Q1 2024.

Aigen Investment Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2024 after selling out during the quarter.
Aigen Investment Management sold 19,569 Revance Therapeutics, Inc. shares in Q1 2024, an estimated $172K.
Aigen Investment Management first reported a position in Revance Therapeutics, Inc. in Q4 2019 and held it in 9 quarters.
Aigen Investment Management's Revance Therapeutics, Inc. position peaked at $1.37M in Q2 2023.
188 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2024.

Based on Aigen Investment Management's 13F filing for Q1 2024, filed 14 May 2024.